Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Topiramate as a Disease Modifying Therapy for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)

NCT02878798 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.

NCT NCT02878798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02878798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Topiramate as a Disease Modifying Therapy for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Lead sponsor
Virginia Commonwealth University
Phase
Phase 2
Overall status
Completed
Start date
February 12, 2018
Completion date
September 28, 2021
Enrollment
132 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

cryptogenic sensory peripheral neuropathy in metabolic syndrome